TransCode Therapeutics Inc Aktie News

Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON , Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consult...

Safety primary endpoint achieved Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial RECIST data with apparent stable disease lasting over 4 months in 44% of patients (7 out of 16) Safety and durability profile consistent with known mechanism of action Early signals support advancement to a Phase 2a clinical trial with established treatment do...